capmatinib dihydrochloride monohydrate

Spain

Drugs containing this active substance

  • TABRECTA 150 MG FILM-COATED TABLETS

    It is used to treat adults with a type of advanced or metastatic non-small cell lung cancer (NSCLC), provided that the cancer is caused by a mutation in the gene that produces the MET enzyme.

    Form: tablets, film-coated

    Active substance Dosage
    capmatinib dihydrochloride monohydrate 183 mg

    ATC: L01E L01EP L01EP01

    Manufacturer: Novartis Europharm Limited

  • TABRECTA 200 MG FILM-COATED TABLETS

    It is used to treat adult patients with a type of non-small cell lung cancer (NSCLC) that is advanced or has spread to other parts of the body, provided that the cancer is caused by a mutation in a gene that produces the MET enzyme.

    Form: tablets, film-coated

    Active substance Dosage
    capmatinib dihydrochloride monohydrate 244 mg

    ATC: L01E L01EP L01EP01

    Manufacturer: Novartis Europharm Limited